NCT03053440 · OUTCOME

Percentage of Participants With Resolution of All Treatment-precipitating Symptoms

A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM) · Source last updated 2024-10-26

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: Percentage of Participants
Interval / dispersion: Not reported
Time frame: Up to approximately 5 years and 5 months

Analysis population: ITT Analysis Set

Groups in this outcome

Arm A: Ibrutinib

Participants diagnosed with WM with mutated MYD88 gene received 420 mg ibrutinib once daily orally until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor

Arm B: Zanubrutinib

Participants diagnosed with WM with mutated MYD88 gene received 160 mg zanubrutinib twice daily orally until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Arm A: Ibrutinib	99
Arm B: Zanubrutinib	102

Reported measurements

Source class 1

Values in Percentage of Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Arm A: Ibrutinib	78.6	Not reported	Not reported	Not reported	Not reported
Arm B: Zanubrutinib	79.2	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
78.6
group Id
OG001
value
79.2

denoms

counts
group Id
OG000
value
99
group Id
OG001
value
102
units
Participants

groups

description
Participants diagnosed with WM with mutated MYD88 gene received 420 mg ibrutinib once daily orally until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor
id
OG000
title
Arm A: Ibrutinib
description
Participants diagnosed with WM with mutated MYD88 gene received 160 mg zanubrutinib twice daily orally until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor
id
OG001
title
Arm B: Zanubrutinib

param Type

NUMBER

population Description

ITT Analysis Set

reporting Status

POSTED

time Frame

Up to approximately 5 years and 5 months

title

Percentage of Participants With Resolution of All Treatment-precipitating Symptoms

type

SECONDARY

unit Of Measure

Percentage of Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice